Compass Therapeutics, Inc. (CMPX) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Greetings and welcome to Compass Therapeutics second quarter 2025 earnings and business update call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It's now my pleasure to introduce Anna Guilford, Chief of Staff. Thank you. You may begin. Good morning and thank you for joining us. My name is Anna Gifford. I'm chief of staff at Compass Therapeutics. With me today is Dr. Thomas Ritz, the CEO and vice chair of the Compass Board. Our CFO, Barry Shin, will also join us for a short Q&A following Tom's comments. Earlier this morning, we released our financial results and a business update for the second quarter. The slide presentation accompanying this webcast and a copy of the press release are available on our website. Please note, we'll be making forward-looking statements on today's webcast. These forward-looking statements are described in our press release issued today in the company's SEC filing. With that, I'd like to turn this call over to Tom. Thank you. We're incredibly excited today to be hosting this call with you this morning. As Anna just mentioned, earlier today we released our quarterly financials for Q2 2025. In addition to the financials, we also provided very important updates for three of our development programs. These updates are summarized on the next slide, and I'll then provide additional details for each of these program updates. Most importantly today, for our lead program, Tevesimig, the DLL4 VEGFA bispecific antibody in the ongoing randomized trial in patients with advanced biliary tract cancer, There are currently fewer tota...